First Horizon Advisors Inc. lowered its holdings in Cencora, Inc. (NYSE:COR – Free Report) by 4.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,809 shares of the company’s stock after selling 530 shares during the period. First Horizon Advisors Inc.’s holdings in Cencora were worth $2,433,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Howe & Rusling Inc. increased its holdings in Cencora by 0.3% in the 3rd quarter. Howe & Rusling Inc. now owns 20,162 shares of the company’s stock valued at $4,538,000 after purchasing an additional 66 shares in the last quarter. Commerce Bank boosted its position in shares of Cencora by 0.5% in the third quarter. Commerce Bank now owns 22,507 shares of the company’s stock worth $5,066,000 after buying an additional 114 shares during the period. Northwest Bancshares Inc. acquired a new stake in shares of Cencora in the third quarter valued at about $5,319,000. Premier Fund Managers Ltd purchased a new stake in shares of Cencora during the 3rd quarter valued at about $8,982,000. Finally, Avior Wealth Management LLC lifted its position in Cencora by 66.5% during the 3rd quarter. Avior Wealth Management LLC now owns 6,004 shares of the company’s stock worth $1,351,000 after acquiring an additional 2,398 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Cencora Trading Up 0.9 %
NYSE COR opened at $243.20 on Thursday. The firm has a market capitalization of $47.92 billion, a PE ratio of 32.38, a price-to-earnings-growth ratio of 1.60 and a beta of 0.44. Cencora, Inc. has a one year low of $195.83 and a one year high of $251.56. The company has a 50-day simple moving average of $232.82 and a 200-day simple moving average of $231.29. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.
Cencora Increases Dividend
Wall Street Analyst Weigh In
Several brokerages have issued reports on COR. Robert W. Baird increased their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Evercore ISI boosted their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. UBS Group raised their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Finally, Bank of America reaffirmed a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $271.20.
Get Our Latest Research Report on COR
Insider Buying and Selling
In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 15.80% of the company’s stock.
Cencora Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Recommended Stories
- Five stocks we like better than Cencora
- What Are Some of the Best Large-Cap Stocks to Buy?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Williams-Sonoma Stock: Buy It and Never Let It Go
- What is the FTSE 100 index?
- 5 Dividend ETFs to Buy and Hold Forever
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.